714 Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors

• Mario Sznol,
• Adil Daud,
• Scott M Turner,
• Chris N Barnes,
• Susan Owen,
• Eric A Lefebvre,
• Hardean E Achneck

Affiliations

Mario Sznol

3Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

Adil Daud

2University of California, San Francisco, San Francisco, CA, USA

Scott M Turner

4Pliant Therapeutics, South San Francisco, CA, USA

Chris N Barnes

2Pliant Therapeutics Inc., South San Francisco, CA, USA

Susan Owen

2Pliant Therapeutics Inc., South San Francisco, CA, USA

Eric A Lefebvre

2Pliant Therapeutics Inc., South San Francisco, CA, USA

Hardean E Achneck

2Pliant Therapeutics Inc., South San Francisco, CA, USA